$NXEN
NEXIEN BIOPHARMA, INC. Stock $nxen

$nxen Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-K Financial Statement

#000149315222026974 Filed on September 28, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$74.32K	$71.15K	$564.0K
YoY Change	-35.34%	-59.34%	-69.41%
% of Gross Profit
Research & Development	$0.00		$0.00
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$74.32K	$71.15K	$564.0K
YoY Change	-35.34%	-59.34%	-69.41%
Operating Profit
YoY Change
Interest Expense	-$20.56K	-$25.85K	-$62.37K
YoY Change	203.69%	285.82%	285.48%
% of Operating Profit
Other Income/Expense, Net	-$20.56K		-$62.37K
YoY Change	203.59%		285.56%
Pretax Income	-$94.87K	-$97.00K	-$626.4K
YoY Change	-22.05%	-46.61%	-66.32%
Income Tax
% Of Pretax Income
Net Earnings	-$94.87K	-$97.00K	-$626.4K
YoY Change	-22.05%	-46.61%	-66.32%
Net Earnings / Revenue
Basic Earnings Per Share	$0.00		-$0.01
Diluted Earnings Per Share	-$1.553K	-$1.606K	-$10.83K
COMMON SHARES
Basic Shares Outstanding	61.27M shares		57.86M shares
Diluted Shares Outstanding	61.07M shares		57.86M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$101.2K	$116.9K	$116.9K
YoY Change	2641.19%	548.0%	548.0%
Cash & Equivalents	$101.1K	$116.9K
Short-Term Investments
Other Short-Term Assets	$3.810K	$7.620K	$7.620K
YoY Change	1.6%	1.6%	1.6%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$105.0K	$124.5K	$124.5K
YoY Change	1310.73%	387.54%	387.55%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$105.0K	$124.5K	$124.5K
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$105.0K	$124.5K	$124.5K
YoY Change	1310.73%	387.54%	387.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$25.70K	$20.40K	$20.40K
YoY Change	184.61%	219.75%	219.75%
Accrued Expenses	$45.00K	$45.00K	$45.00K
YoY Change	125.0%	125.0%	125.0%
Deferred Revenue
YoY Change
Short-Term Debt	$194.9K	$176.7K	$176.7K
YoY Change	959.08%	1265.77%	1265.77%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$265.6K	$242.1K	$242.1K
YoY Change	459.9%	515.78%	515.77%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$265.6K	$242.1K	$242.1K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$265.6K	$242.1K	$242.1K
YoY Change	459.9%	515.78%	515.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$11.03M	-$10.93M
YoY Change		6.08%
Common Stock	$6.127K	$6.052K
YoY Change		8.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$160.6K	-$117.6K	-$117.6K
YoY Change
Total Liabilities & Shareholders Equity	$105.0K	$124.5K	$124.5K
YoY Change	1310.73%	387.54%	387.55%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022
OPERATING ACTIVITIES
Net Income	-$94.87K	-$97.00K	-$626.4K
YoY Change	-22.05%	-46.61%	-66.32%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$15.75K	-$23.32K	-$75.14K
YoY Change	9.76%	-28.29%	-17.2%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities		$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000	$174.0K
YoY Change		-100.0%	77.55%
NET CHANGE
Cash From Operating Activities	-$15.75K	-23.32K	-$75.14K
Cash From Investing Activities		0.000
Cash From Financing Activities		0.000	$174.0K
Net Change In Cash	-$15.75K	-23.32K	$98.86K
YoY Change		86.26%	1263.54%
FREE CASH FLOW
Cash From Operating Activities	-$15.75K	-$23.32K	-$75.14K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022	NXEN	Shares Issued For Settlement Of Accounts Payable SharesIssuedForSettlementOfAccountsPayable		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001625288
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q2	NXEN	Common Stock Subject To Forfeiture CommonStockSubjectToForfeiture		usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2021	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue		usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2021	NXEN	Fair Value Of Warrants Issued FairValueOfWarrantsIssued		usd
CY2021	NXEN	Imputed Interest On Related Party Advances ImputedInterestOnRelatedPartyAdvances		usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts		usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022	NXEN	Proceeds From Convertible Debt Related Party ProceedsFromConvertibleDebtRelatedParty		usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2021	NXEN	Shares Issued To Officers For Services SharesIssuedToOfficersForServices		usd
CY2021	NXEN	Discount On Convertible Debt DiscountOnConvertibleDebt		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber		shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2022Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-55320
CY2022	dei	Entity Registrant Name EntityRegistrantName	NEXIEN BIOPHARMA, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2049376
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	4340 East Kentucky Avenue
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 206
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Glendale
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80246
CY2022	dei	City Area Code CityAreaCode	303
CY2022	dei	Local Phone Number LocalPhoneNumber	495-7583
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Public Float EntityPublicFloat	1702974	usd
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	61272196	shares
CY2022	dei	Auditor Firm AuditorFirmId	2738
CY2022	dei	Auditor Name AuditorName	M&K CPAS, PLLC
CY2022	dei	Auditor Location AuditorLocation	Houston, TX
CY2022Q2	us-gaap	Cash Cash	116898	usd
CY2021Q2	us-gaap	Cash Cash	18041	usd
CY2022Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	7620	usd
CY2021Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	7500	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	124518	usd
CY2021Q2	us-gaap	Assets Current AssetsCurrent	25541	usd
CY2022Q2	us-gaap	Assets Assets	124518	usd
CY2021Q2	us-gaap	Assets Assets	25541	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	20395	usd
CY2021Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6375	usd
CY2022Q2	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	45000	usd
CY2021Q2	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	20000	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	30452	usd
CY2021Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	52059	usd
CY2022Q2	NXEN	Convertible Notes Payable Related Party ConvertibleNotesPayableRelatedParty	34548	usd
CY2021Q2	NXEN	Convertible Notes Payable Related Party ConvertibleNotesPayableRelatedParty	12941	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	28274	usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	142180	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	242123	usd
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	39316	usd
CY2022Q2	us-gaap	Liabilities Liabilities	242123	usd
CY2021Q2	us-gaap	Liabilities Liabilities	39316	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60522196	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60522196	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55772196	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55772196	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	6052	usd
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	5577	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	10759051	usd
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	10476004	usd
CY2022Q2	NXEN	Stock Payable StockPayable	50750	usd
CY2021Q2	NXEN	Stock Payable StockPayable	35000	usd
CY2021Q2	NXEN	Common Stock Subject To Forfeiture CommonStockSubjectToForfeiture	-223255	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10933458	usd
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10307101	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-117605	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-13775	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	124518	usd
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25541	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	33230	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	43710	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	530762	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1800057	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	563992	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	1843767	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	17945	usd
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	3234	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	44420	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	12941	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-62365	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-16175	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-626357	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1859942	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57860108	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55399643	shares
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-6365	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	25161	usd
CY2021	NXEN	Stock Issued During Period Value Issuance Of Stock For Accounts Payable StockIssuedDuringPeriodValueIssuanceOfStockForAccountsPayable	13500	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	271250	usd
CY2021	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	1093668	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	348953	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	65000	usd
CY2021	NXEN	Stock Issued During Period Common Stock Issuable To Officers StockIssuedDuringPeriodCommonStockIssuableToOfficers	35000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1859942	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-13775	usd
CY2022	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	223255	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	155750	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	110264	usd
CY2022	NXEN	Stock Issued During Period Exercise Of Warrant Issued For Consulting Services StockIssuedDuringPeriodExerciseOfWarrantIssuedForConsultingServices	2250	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	18558	usd
CY2022	NXEN	Adjustments To Additional Paid In Capital Warrant Issued For Convertible Debt AdjustmentsToAdditionalPaidInCapitalWarrantIssuedForConvertibleDebt	8825	usd
CY2022	NXEN	Adjustments To Additional Paid In Capital Imputed Interest On Related Party Advances AdjustmentsToAdditionalPaidInCapitalImputedInterestOnRelatedPartyAdvances	3625	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-626357	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-117605	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-626357	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1859942	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	348953	usd
CY2022	NXEN	Fair Value Of Shares Issued For Acquisition FairValueOfSharesIssuedForAcquisition	223255	usd
CY2021	NXEN	Fair Value Of Shares Issued For Acquisition FairValueOfSharesIssuedForAcquisition	1093668	usd
CY2022	NXEN	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	-110264	usd
CY2022	NXEN	Imputed Interest On Related Party Advances ImputedInterestOnRelatedPartyAdvances	3625	usd
CY2022	NXEN	Stock Issued To Officers And Director StockIssuedToOfficersAndDirector	105000	usd
CY2021	NXEN	Stock Issued To Officers And Director StockIssuedToOfficersAndDirector	271250	usd
CY2022	NXEN	Stock Issuable To Officers StockIssuableToOfficers	50750	usd
CY2021	NXEN	Stock Issuable To Officers StockIssuableToOfficers	35000	usd
CY2022	NXEN	Amortization Of Financing Costs And Discounts Related Party AmortizationOfFinancingCostsAndDiscountsRelatedParty	21606	usd
CY2021	NXEN	Amortization Of Financing Costs And Discounts Related Party AmortizationOfFinancingCostsAndDiscountsRelatedParty	12941	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	22814	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	120	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-4500	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	14020	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2885	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-75143	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-90745	usd
CY2021	NXEN	Proceeds From Convertible Debt Related Party ProceedsFromConvertibleDebtRelatedParty	78000	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	146750	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2250	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	25000	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	20000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	174000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	98000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	98857	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7255	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18041	usd
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10786	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	116898	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18041	usd
CY2022	NXEN	Shares Issued To Officers For Services SharesIssuedToOfficersForServices	140000	usd
CY2022	NXEN	Discount On Convertible Debt DiscountOnConvertibleDebt	32633	usd
CY2021	NXEN	Shares Issued For Settlement Of Accounts Payable SharesIssuedForSettlementOfAccountsPayable	13500	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	25161	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	5181897	shares
CY2021Q2	NXEN	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Exercise Price Granted SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageExercisePriceGranted	0.0429
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5181897	shares
CY2021Q2	NXEN	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageExercisePrice	0.0429
CY2021	NXEN	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Non Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsOutstandingWeightedAverageRemainingContractualTerms	P4Y4M24D
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10933458	usd
CY2022	NXEN	Working Capital WorkingCapital	117605	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zqQqrskNqKZj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zc6S79H25sfh">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2021Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	2597512	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	2250000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5529409	shares
CY2021Q2	NXEN	Convertible Notes Payable Related Party ConvertibleNotesPayableRelatedParty	12941	usd
CY2021Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	52059	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	0	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	0	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zw4B0Hlw9Cnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zMmRGGhPh7M3">Concentrations of Credit Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are deposited with major banks in the United States of America. Management believes that such financial institutions are financially sound and, accordingly, minimal credit risk exists with respect to these financial instruments. The Company does not have any significant off-balance-sheet concentration of credit risk.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84B_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zuYtqjJgEQ7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zUN3JxZd3Lb4">Reclassifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts in the consolidated financial statements for prior year periods have been reclassified to conform with the current year periods presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NEXIEN BIOPHARMA, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years Ended June 30, 2022 and 2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 – Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	NXEN	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageExercisePrice	0.0429
CY2022	NXEN	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Non Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsOutstandingWeightedAverageRemainingContractualTerms	P3Y4M9D
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	140000	usd
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2995000	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.55
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5000000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.08
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7995000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.26
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y6M
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7995000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.26
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y8M12D
CY2022	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	On December 22, 2017, the 2017 Tax Cuts and Jobs Act (the Tax Act) was enacted into law and the new legislation contains several key tax provisions that affected us, including a reduction of the corporate income tax rate to 21% effective January 1, 2018.
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2704000	usd
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2250000	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2022Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	146750	usd
CY2022Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	23704	usd
CY2022Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	142180	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	28274	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	22814	usd
CY2022Q2	NXEN	Convertible Notes Payable Related Party ConvertibleNotesPayableRelatedParty	34548	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	30452	usd
CY2021Q2	NXEN	Convertible Notes Payable Related Party ConvertibleNotesPayableRelatedParty	12941	usd
CY2021Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	52059	usd
CY2022Q2	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	45000	usd
CY2021Q2	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	20000	usd
CY2022Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	15750	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	140000	usd
CY2022Q2	NXEN	Convertible Notes Payable Related Party ConvertibleNotesPayableRelatedParty	34548	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	30452	usd
CY2022	NXEN	Operating Loss Carryforwards Expiration Date Description OperatingLossCarryforwardsExpirationDateDescription	The available net operating loss carry forwards expire in various years through 2041. No tax benefit has been reported in the financial statements because the Company believes there is a 50% or greater chance the carry forwards will expire unused.
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.24	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.03	pure
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	650691	usd
CY2021Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	617321	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	650691	usd
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	617321	usd
CY2022	NXEN	Increase Decrease In Net Operating Loss Benefit IncreaseDecreaseInNetOperatingLossBenefit	-33370	usd
CY2021	NXEN	Increase Decrease In Net Operating Loss Benefit IncreaseDecreaseInNetOperatingLossBenefit	-52348	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	33370	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	52348	usd

Files In Submission

Name	View Source	Status
0001493152-22-026974-index-headers.html	Edgar Link	pending
0001493152-22-026974-index.html	Edgar Link	pending
0001493152-22-026974.txt	Edgar Link	pending
0001493152-22-026974-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nxen-20220630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
nxen-20220630_def.xml	Edgar Link	unprocessable
nxen-20220630_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
nxen-20220630_cal.xml	Edgar Link	unprocessable
nxen-20220630_lab.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NXEN
NEXIEN BIOPHARMA, INC. Stock $nxen

2022 Q3 Form 10-K Financial Statement

#000149315222026974 Filed on September 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NXEN NEXIEN BIOPHARMA, INC. Stock $nxen

2022 Q3 Form 10-K Financial Statement

#000149315222026974 Filed on September 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NXEN
NEXIEN BIOPHARMA, INC. Stock $nxen